KROS Keros Therapeutics, Inc. Stock Quote

KROS [NASD]

Index	-	P/E	-	EPS (ttm)	-1.83	Insider Own	0.30%	Shs Outstand	20.18M	Perf Week	-10.46%
Market Cap	1.28B	Forward P/E	-	EPS next Y	-2.54	Insider Trans	119.67%	Shs Float	18.31M	Perf Month	1.98%
Income	-37.30M	PEG	-	EPS next Q	-0.57	Inst Own	90.10%	Short Float	3.77%	Perf Quarter	-20.81%
Sales	2.50M	P/S	512.10	EPS this Y	-824.00%	Inst Trans	28.34%	Short Ratio	4.51	Perf Half Y	4.77%
Book/sh	6.48	P/B	9.05	EPS next Y	38.60%	ROA	-	Target Price	86.25	Perf Year	-
Cash/sh	6.13	P/C	9.57	EPS next 5Y	-	ROE	-	52W Range	19.10 - 88.80	Perf YTD	-16.90%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	73.40%	52W High	-33.99%	Beta	-
Dividend %	-	Quick Ratio	20.00	Sales past 5Y	-	Gross Margin	-	52W Low	206.91%	ATR	5.48
Employees	32	Current Ratio	20.00	Sales Q/Q	-	Oper. Margin	-	RSI (14)	42.85	Volatility	10.75% 9.23%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	65.10%	Profit Margin	-	Rel Volume	0.71	Prev Close	55.25
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	153.33K	Price	58.62
Recom	1.50	SMA20	-7.86%	SMA50	-12.19%	SMA200	13.64%	Volume	113,380	Change	6.10%

Dec-08-20

Reiterated

H.C. Wainwright

Buy

$50 → $100

May-04-20

Initiated

SVB Leerink

Outperform

$42

May-04-20

Initiated

Piper Sandler

Overweight

$35

May-04-20

Initiated

Jefferies

Buy

$37

May-04-20

Initiated

H.C. Wainwright

Buy

$50

Mar-05-21 08:00AM	Keros Therapeutics Presents Results from Preclinical Studies of KER-050 and ALK2 Inhibitors at the European School of Haematology (ESH) 2nd Translational Research E-Conference GlobeNewswire +6.10%
Mar-02-21 08:00AM	Keros Therapeutics to Present at the H.C. Wainwright Global Life Sciences 2021 Virtual Conference GlobeNewswire -6.73%
Feb-17-21 08:00AM	Keros Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference GlobeNewswire
Jan-25-21 02:45AM	Companies Like Keros Therapeutics (NASDAQ:KROS) Are In A Position To Invest In Growth Simply Wall St.
Dec-21-20 08:00AM	Keros Therapeutics Announces Addition to NASDAQ Biotechnology Index GlobeNewswire -6.83%
Dec-17-20 08:00AM	Keros Therapeutics Appoints Mary Ann Gray, Ph.D., to its Board of Directors GlobeNewswire +5.31%
Dec-09-20 03:44PM	Is KROS A Good Stock To Buy Now? Insider Monkey -5.92%
Dec-08-20 04:03PM	Boeing, Kratos To Build Skyborg Drones For Air Force Experiments Investor's Business Daily +6.77%
Dec-07-20 08:00AM	Keros Therapeutics Presents Clinical Trial and Preclinical Study Results from its ALK2 Inhibitor Program, Including KER-047 Phase 1 Data, and KER-050 Preclinical Data, at the Virtual 62nd American Society of Hematology Annual Meeting and Exposition GlobeNewswire
Nov-17-20 04:01PM	Keros Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Nov-16-20 08:00AM	Keros Therapeutics to Present at the Jefferies Virtual London Healthcare Conference GlobeNewswire +15.48%
Nov-12-20 10:11PM	Keros Therapeutics Announces Pricing of Public Offering of Common Stock GlobeNewswire
Nov-10-20 05:12PM	Keros Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire
04:17PM	Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2020 Financial Results GlobeNewswire
Nov-09-20 08:00AM	Global Health Sciences Fund (Quark Venture LP and GF Securities) Announces Portfolio Company SQZ Biotechnologies IPO GlobeNewswire
Nov-04-20 04:01PM	Keros Therapeutics to Present at the Virtual 62nd American Society of Hematology Annual Meeting and Exposition GlobeNewswire
Oct-27-20 08:35AM	How Many Keros Therapeutics, Inc. (NASDAQ:KROS) Shares Did Insiders Buy, In The Last Year? Simply Wall St. +7.93%
Oct-20-20 08:00AM	Keros Therapeutics, Inc. Announces Dosing of First Participants in Phase 2 Clinical Trial of KER-050 in Myelodysplastic Syndromes (MDS) GlobeNewswire
Sep-14-20 07:01AM	Keros Therapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference GlobeNewswire
Sep-11-20 04:01PM	Keros Therapeutics Presents Results from Preclinical Studies Investigating KER-012 at the American Society for Bone and Mineral Research 2020 Annual Meeting GlobeNewswire -5.80%
Aug-13-20 07:00AM	Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2020 Financial Results GlobeNewswire +8.44%
Aug-10-20 08:00AM	Keros Therapeutics to be Featured on The Balancing Act's "Behind the Mystery" Rare Disease Series GlobeNewswire
Aug-04-20 08:00AM	Keros Therapeutics, Inc. Announces Completion of Dosing of Planned Cohorts in KER-047 Phase 1 Trial and Provides Program Update GlobeNewswire
Jul-29-20 10:12AM	Here's Why We're Not Too Worried About Keros Therapeutics' (NASDAQ:KROS) Cash Burn Situation Simply Wall St. +5.33%
Jun-26-20 07:01AM	Keros Therapeutics Set to Join Russell 2000® Index GlobeNewswire
Jun-24-20 08:34AM	Keros Therapeutics (KROS) in Focus: Stock Moves 6.8% Higher Zacks
Jun-12-20 07:01AM	Keros Therapeutics Presents Results from Clinical and Preclinical Studies Investigating KER-050, along with Preclinical Data from its ALK2 Inhibitor Program, at the European Hematology Association 2020 Annual Meeting GlobeNewswire
May-28-20 07:01AM	Keros Therapeutics To Present At The Jefferies 2020 Virtual Healthcare Conference GlobeNewswire
May-22-20 07:00AM	Keros Therapeutics Reports Recent Business Highlights and First Quarter 2020 Financial Results GlobeNewswire
May-14-20 09:15AM	Keros Therapeutics to Present at the Virtual 25th Annual Congress of the European Hematology Association GlobeNewswire
May-05-20 11:46AM	3 Biotech Stocks With Plenty of Upside in the Pipeline TipRanks
Apr-13-20 04:01PM	Keros Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire +7.70%
Apr-07-20 08:45PM	Keros Therapeutics Announces Pricing of Initial Public Offering of Common Stock ACCESSWIRE

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva, or FOP, and is currently in a Phase 1 clinical trial; and KER-012 being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension, or PAH. The company was founded in 2015 and is headquartered in Lexington, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Knowles Julius	Director	Mar 04	Sale	55.48	11,632	645,385	420,825	Mar 05 07:44 PM
Knowles Julius	Director	Mar 03	Sale	57.36	12,327	707,115	425,417	Mar 05 07:44 PM
Knowles Julius	Director	Mar 02	Sale	58.75	10,711	629,285	430,283	Mar 03 08:40 PM
Knowles Julius	Director	Mar 01	Sale	63.09	12,979	818,793	434,511	Mar 03 08:40 PM
Lachey Jennifer	Chief Scientific Officer	Feb 26	Option Exercise	0.11	33,200	3,652	61,191	Mar 01 04:54 PM
Knowles Julius	Director	Feb 18	Sale	63.11	2,944	185,785	439,634	Feb 18 06:46 PM
Knowles Julius	Director	Feb 17	Sale	61.05	16,061	980,588	440,796	Feb 18 06:46 PM
Knowles Julius	Director	Feb 16	Sale	59.89	9,612	575,671	447,136	Feb 18 06:46 PM
Knowles Julius	Director	Feb 12	Sale	61.53	7,468	459,495	450,930	Feb 16 05:50 PM
Lachey Jennifer	Chief Scientific Officer	Feb 11	Option Exercise	0.30	5,300	1,590	33,291	Feb 16 05:47 PM
Ordonez Claudia	Chief Medical Officer	Feb 11	Option Exercise	0.48	1,000	480	1,000	Feb 16 05:49 PM
Knowles Julius	Director	Feb 11	Sale	64.82	11,561	749,441	453,878	Feb 16 05:50 PM
Ordonez Claudia	Chief Medical Officer	Feb 11	Sale	64.84	1,000	64,841	0	Feb 16 05:49 PM
Lachey Jennifer	Chief Scientific Officer	Feb 11	Sale	64.91	5,300	344,017	27,991	Feb 16 05:47 PM
Nussbaum Ran	Director	Nov 17	Buy	50.00	60,000	3,000,000	2,288,151	Nov 19 04:40 PM
Kariv Tomer	Director	Nov 17	Buy	50.00	60,000	3,000,000	2,288,151	Nov 19 04:39 PM
Pontifax Management 4 G.P. (20	10% Owner	Nov 17	Buy	50.00	60,000	3,000,000	2,288,151	Nov 19 04:38 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience